Detail akcie Sareum Holdings Rg online

Business Summary: Sareum Holdings plc is a United Kingdom-based clinical-stage biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company is focused on advancing inhibitors of the JAK kinase family into clinical development for autoimmune disease and cancer. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development. The Company is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. Additionally, the Company owns the license for SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, Sareum Holdings Plc revenues was not reported. Net loss increased 30% to L4.4M. Higher net loss reflects Other operating income decrease from L22K (income) to L0K. Basic Earnings per Share excluding Extraordinary Items remained flat at -L0.04.